Arboretum LifeSciences Raises $30M Series A

The gap between a genomic insight and a routine clinical decision is filled with consent, ordering, counseling, data integration, follow-up, and a long list of people who already have full calendars. Arboretum LifeSciences is raising money to turn that gap into infrastructure.

The Cambridge, Massachusetts company launched publicly on October 6, 2026 with $30M in Series A financing. The named investor group includes F-Prime, GV, .406 Ventures, Hims & Hers, and Amgen, alongside other healthcare investors.

Arboretum is building a molecular-information network meant to serve two sides of medicine at once. Health systems get support for clinically indicated genetic testing and longitudinal patient registries. Drug developers get access to a model designed for genomic stratification, patient matching, target discovery, and more focused clinical development. The financing matters because both sides must work together before precision medicine can move from a promising result to a repeatable operating system for common disease.

What Arboretum Is Building

Arboretum is led by co-founder and CEO Anthony Philippakis, MD, PhD, and president Clare Bernard, PhD. Philippakis is also a general partner at GV and previously served as chief data officer at the Broad Institute. Arboretum says its broader team comes from the Broad Institute's Data Sciences Platform and includes experience in large-scale genomics, software, clinical research, registry development, and human-subjects compliance.

The model starts with genetic testing inside clinical workflows. Arboretum works with providers to identify clinically appropriate patients, support testing, return relevant findings, and invite consenting participants into longitudinal research. That registry can then connect molecular information with clinical history over time.

For patients, the immediate promise is more precise risk assessment and care. For health systems, the network can support research without requiring every institution to assemble the same testing, consent, data, and trial-enrollment machinery from scratch. For biopharma, the commercial value sits in finding biologically defined populations that may respond differently to treatment and recruiting those patients into better-targeted studies.

Arboretum describes applications across cardiovascular, metabolic, autoimmune, and neurodegenerative disease. Its current testing materials detail hereditary cardiovascular and hereditary cancer programs. Those are company plans and program descriptions, not published proof that the network has improved outcomes or shortened trials at scale.

The Health-System Network Is the Product

Arboretum named Advocate Health, Geisinger, Providence Healthcare, and Cardiovascular Associates of America as initial healthcare delivery partners. Each relationship is structured around a different operating environment rather than a single software installation.

At Advocate Health, the plan supports a national cardiogenetics service line and registry. At Geisinger, Arboretum is integrating clinical-grade genomic results with the MyCode-Connect biobank. Providence is pairing testing and research infrastructure with existing registries. Cardiovascular Associates of America is adding point-of-care genetic testing across a specialty-practice network.

That variety is important. Genetic testing does not enter an empty room. It has to fit clinical guidelines, insurance policies, lab operations, electronic records, counseling capacity, privacy controls, and the habits of physicians who are responsible for decisions after the result arrives. Arboretum's business depends on making those handoffs ordinary enough that the data can also support research.

The four initial partners give Arboretum credible starting points, but the company has not disclosed patient counts, enrollment rates, revenue, trial volume, or clinical outcomes. Axios reported that Arboretum is open to more health-system partners as it expands the platform. Network breadth will matter, but the quality, consent model, longitudinal depth, and usefulness of the data will matter more.

Why Investors Are Funding the Handoff

Precision medicine has already changed cancer and rare-disease care by making molecular differences more central to diagnosis and treatment. Common diseases create a different scaling problem. The affected populations are larger, the biology is heterogeneous, and the path from a genetic signal to a clinical action runs through health systems built around population-level standards.

Arboretum is betting that clinical testing and drug development can share infrastructure. A patient can receive a result that informs present care while, with consent, contributing to longitudinal research. A health system can expand testing and become more capable of running precision trials. A drug developer can use molecular and clinical information to define a subgroup, design a study, or identify eligible patients.

That two-sided model also explains the investor mix. F-Prime, GV, and .406 Ventures bring venture and healthcare-company-building experience. Amgen brings the perspective of a drug developer that depends on better biological segmentation. Hims & Hers brings a consumer-health and care-delivery lens. The group is financing a company that must understand science, software, regulated operations, and the economics of clinical adoption at the same time.

The $30M Series A gives Arboretum room to expand the network and deepen the machinery connecting care with research. It does not resolve the central execution question: whether those relationships can produce durable, representative, consented datasets and measurable improvements for patients and trial sponsors.

What the Series A Puts in Motion

Arboretum enters the market with a stronger foundation than a slide-deck network. It has named health-system partners, a visible team, live testing programs, and investors whose interests span venture capital, biopharma, and consumer care. The company is also early enough that nearly every important business metric remains private.

The next evidence will come from operations. Arboretum will need to show that testing can reach appropriate patients without adding unmanageable work, that findings can return to care teams responsibly, that registries retain participants and useful follow-up, and that research partners can turn the network into better trial decisions. Those are separate jobs connected by the same patient relationship.

If Arboretum succeeds, the useful life of a genetic result will extend beyond a lab report. It will move through care, research, and therapeutic development without losing the patient or the biological signal along the way. The Series A is paying for that continuity while four health-system partnerships begin testing how much of it can become routine.